Compare AbbVie Inc (ABBV) vs Global X FTSE Southeast Asia ETF (ASEA) Price & Performance

AbbVie IncTrade

Global X FTSE Southeast Asia ETFTrade

Price performance (Past 24H)

Key statistics

AbbVie Inc vs Global X FTSE Southeast Asia ETF — how do they compare? AbbVie Inc trades at $248.15 (market cap $441.94B), while Global X FTSE Southeast Asia ETF trades at $21.47. The key difference: AbbVie Inc pays a 2.77% dividend while Global X FTSE Southeast Asia ETF pays none, and Global X FTSE Southeast Asia ETF is trading nearer its 52-week high, AbbVie Inc nearer its low. Which is the better fit depends on your goals.

	ABBV	ASEA
Market Cap	$441.94B	—
Sector	Health	Sector/Thematic
52-Week High	$263.58	$21.53
52-Week Low	$197.38	$16.86
Enterprise Value	$506.19B	—
Dividend Yield	2.77%	—

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbbVie Inc

AbbVie (ABBV) trades at $247.91, up 0.76% today, with a bullish technical signal and strong analyst support. Recent earnings beats and a 70.73% buy consensus highlight robust fundamentals, driven by Skyrizi and Rinvoq growth offsetting Humira declines. Positive news includes Phase 2 ovarian cancer data and institutional stake increases, reinforcing momentum.

Outlook remains positive with a $278.69 price target, though risks include patent cliffs and debt levels. Revenue growth and dividend stability offer appeal, but investors should monitor competitive pressures and regulatory developments for sustained performance.

Global X FTSE Southeast Asia ETF

No Aura AI signal available yet.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

ABBV

Fidelity Dividend ETF's payout is safe but not ideal for steady income due to variable quarterly dividends.24/7 Wall Street · 1 day agoNeutral Two Dividend Aristocrats outperformed the market while two lagged; three new picks show promising dividend growth.24/7 Wall Street · 2 days agoNeutral Healthcare sector leads S&P 500 gains over 3 months with key pharma stocks showing strong innovation and income potential.24/7 Wall Street · 2 days agoBullish View details →

ASEA

View details →

About AbbVie Inc

AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.

About Global X FTSE Southeast Asia ETF

ASEA tracks the performance of the largest companies in Southeast Asia. It provides exposure to key emerging markets including Singapore, Indonesia, Thailand, and Malaysia, with a heavy focus on financials like DBS Group and Bank Central Asia.